Superseded · version 1: TB-500^↗

Related names recorded in this version: N-terminal acetylated 17-23 fragment of thymosin beta-4^↗

A research-peptide name that FDA's substance registry maps to a thymosin beta-4 fragment.^↗

This is preserved historical wording.
It is no longer the current profile. Read the current profile and its correction notice.

What this version reported

FDA's substance registry identifies TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4 and explicitly states that a UNII record does not imply regulatory review or approval.^↗

Organizations named in cited records:

U.S. Food and Drug Administration^↗

Sources for this version

1
TB-500 substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked July 29, 2026